Researchers at King’s College London have shown that an existing genetic test for breast cancer can also predict future breast cancer in women with ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS), two conditions characterized by lesions in breast tissue that can progress into breast cancer. Results of the study, published in Cancer Epidemiology, Biomarker & Prevention , show early potential for this genetic test to inform a more personalized approach when treating these patients.

“Predicting who is most likely to develop invasive breast cancer is vital to offering the best possible treatment options for women, as not all with DCIS or LCIS will go on to develop invasive cancer,” said Jasmine Timbres, clinical information analyst at King’s College London and lead

See Full Page